These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9551671)

  • 21. Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine.
    Meisel H; Preikschat P; Reinke P; Hocher B; Budde K; Bechstein WO; Neuhaus P; Krüger DH; Neumayer HH
    Transpl Int; 1999; 12(4):283-7. PubMed ID: 10460876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A clinical study of allo-hematopoietic stem cell transplantation in HBsAg positive leukemia].
    Chen Y; Xu LP; Liu KY; Liu DH; Han W; Chen H; Zhang YC; Chen YH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2008 Apr; 47(4):316-9. PubMed ID: 18843958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
    Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
    Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion of recurrent delta-positive hepatitis B infection to seronegativity with famciclovir after liver transplantation.
    Klein M; Geoghegan J; Schmidt K; Böckler D; Korn K; Wittekind C; Scheele J
    Transplantation; 1997 Jul; 64(1):162-3. PubMed ID: 9233718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
    Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
    Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients.
    Querido S; Weigert A; Adragão T; Rodrigues L; Jorge C; Bruges M; Machado D
    Transpl Infect Dis; 2019 Feb; 21(1):e13009. PubMed ID: 30295412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation.
    Rayes N; Seehofer D; Bechstein WO; Müller AR; Berg T; Neuhaus R; Neuhaus P
    Clin Transplant; 1999 Dec; 13(6):447-52. PubMed ID: 10617232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
    de Man RA; Bartholomeusz AI; Niesters HG; Zondervan PE; Locarnini SA
    J Hepatol; 1998 Oct; 29(4):669-75. PubMed ID: 9824278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B Virus Vaccination after Allogeneic Hematopoietic Cell Transplantation Prevents Post-Transplantation Hepatitis B Virus Reactivation.
    Hammond SP; Ho VT; Marty FM
    Transplant Cell Ther; 2022 Jul; 28(7):402.e1-402.e5. PubMed ID: 35413458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation.
    Rayes N; Seehofer D; Hopf U; Neuhaus R; Naumann U; Bechstein WO; Neuhaus P
    Transplantation; 2001 Jan; 71(1):96-101. PubMed ID: 11211203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem.
    Liang R; Lau GK; Kwong YL
    J Clin Oncol; 1999 Jan; 17(1):394-8. PubMed ID: 10458258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome.
    Mikulska M; Nicolini L; Signori A; Rivoli G; Del Bono V; Raiola AM; Di Grazia C; Dominietto A; Varaldo R; Ghiso A; Bacigalupo A; Viscoli C
    Clin Microbiol Infect; 2014 Oct; 20(10):O694-701. PubMed ID: 24575948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study.
    Krüger M; Tillmann HL; Trautwein C; Bode U; Oldhafer K; Maschek H; Böker KH; Broelsch CE; Pichlmayr R; Manns MP
    Liver Transpl Surg; 1996 Jul; 2(4):253-62. PubMed ID: 9346658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Failure of reactivation of hepatitis B after liver transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients.
    Maguire D; Heaton ND; Smith HM
    Transplantation; 2002 Feb; 73(3):481-2. PubMed ID: 11884950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation.
    Haller GW; Bechstein WO; Neuhaus R; Raakow R; Berg T; Hopf U; Neuhaus P
    Transpl Int; 1996; 9 Suppl 1():S210-2. PubMed ID: 8959829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature.
    Kempinska A; Kwak EJ; Angel JB
    Clin Infect Dis; 2005 Nov; 41(9):1277-82. PubMed ID: 16206102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
    Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
    Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B immunoglobulin in combination with lamivudine for prevention of hepatitis B virus reactivation in children undergoing bone marrow transplantation.
    Tavil B; Kuşkonmaz B; Kasem M; Demir H; Cetin M; Uçkan D
    Pediatr Transplant; 2006 Dec; 10(8):966-9. PubMed ID: 17096768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH; Bae SC; Song GG
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
    Roque-Afonso AM; Feray C; Samuel D; Simoneau D; Roche B; Emile JF; Gigou M; Shouval D; Dussaix E
    Gut; 2002 Jan; 50(1):95-9. PubMed ID: 11772974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.